Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)

CONTEXT: Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for treatment of type 2 diabetes (T2D). SURPASS-1, a phase 3 trial of tirzepatide monotherapy in people with early T2D, enables evaluating effects of tirzepatide on pancreatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Clare J, Mao, Huzhang, Thieu, Vivian T, Landó, Laura Fernández, Thomas, Melissa K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157777/
https://www.ncbi.nlm.nih.gov/pubmed/37153701
http://dx.doi.org/10.1210/jendso/bvad056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157777/
https://www.ncbi.nlm.nih.gov/pubmed/37153701
http://dx.doi.org/10.1210/jendso/bvad056

Ejemplares similares